MAGEA4 and hepatocellular carcinoma: For example, it has been shown to be effective in melanoma by targeting the New York esophageal squamous cell carcinoma (NY-ESO-1) antigen [41]; effective for synovial sarcoma, ovarian cancer, and head and neck cancer treatment by recognizing melanoma antigen gene A4 (MAGE-A4) antigen [42,43]; and promising against hepatocellular carcinoma (HCC) via identification of alpha-fetoprotein (AFP) antigen [44].